Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Standing Alone While Standing Together: A Conversation With Millennium CEO Dunsire (Part 2 Of 2)

This article was originally published in PharmAsia News

Executive Summary

Millennium Pharmaceuticals reached its one-year anniversary as the Takeda Oncology Company on May 14. Millennium Pharmaceuticals CEO Deborah Dunsire sat down recently with "The Pink Sheet" DAILY for a conversation about the changes seen in that first year.

You may also be interested in...

"A Quantum Leap In Resources": Millennium CEO Dunsire In A Conversation On The Firm's First Year As Part Of Takeda (Part 1 Of 2)

On May 14, Millennium Pharmaceuticals marked its one-year anniversary as the Takeda Oncology company.

Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition

Takeda's acquisition of Millennium for $8.8 billion will extend the Japanese drug maker's presence in oncology and help stem the loss of revenues as key drugs go generic. Takeda announced plans to acquire the Cambridge, Mass.-based biotech April 10 for $25 per share, a 53 percent premium over the April 9 closing price

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts